ImpriMed: Precision Medicine Company Secures $23 Million To Improve Cancer Treatment
By Amit Chowdhry ● Dec 21, 2023
ImpriMed - a leading precision medicine startup focused on utilizing AI to improve cancer treatment, recently announced the close of a $23 million Series A funding round, led by SBVA. And HRZ Han River Partners, SK Telecom, KDB Silicon Valley, Ignite Innovation Fund, Samyang Chemical Group, Murex Partners, and Byucksan also participated in this round.